LAVA Therapeutics NV (NASDAQ:LVTX) — Market Cap & Net Worth
Market Cap & Net Worth: LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (NASDAQ:LVTX) has a market capitalization of $45.77 Million ($45.77 Million) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22323 globally and #4951 in its home market, demonstrating a -3.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LAVA Therapeutics NV's stock price $1.74 by its total outstanding shares 26305295 (26.31 Million). Also see LAVA Therapeutics NV asset portfolio for a full breakdown of the balance sheet.
LAVA Therapeutics NV Market Cap History: 2021 to 2025
LAVA Therapeutics NV's market capitalization history from 2021 to 2025. Data shows change from $144.68 Million to $45.77 Million (-36.23% CAGR). Also see how efficiently does LAVA Therapeutics NV generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
LAVA Therapeutics NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #645 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #2122 of 3165 |
Weight: LAVA Therapeutics NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LAVA Therapeutics NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LAVA Therapeutics NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LAVA Therapeutics NV share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.09x
LAVA Therapeutics NV's market cap is 2.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $144.68 Million | $5.00 Million | -$45.35 Million | 28.94x | N/A |
| 2022 | $92.07 Million | $19.39 Million | -$31.91 Million | 4.75x | N/A |
| 2023 | $41.56 Million | $6.77 Million | -$41.87 Million | 6.14x | N/A |
| 2024 | $25.02 Million | $11.98 Million | -$25.11 Million | 2.09x | N/A |
Competitor Companies of LVTX by Market Capitalization
Companies near LAVA Therapeutics NV in the global market cap rankings as of September 16, 2026. Review LVTX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to LAVA Therapeutics NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
LAVA Therapeutics NV Historical Marketcap From 2021 to 2025
Between 2021 and today, LAVA Therapeutics NV's market cap moved from $144.68 Million to $ 45.77 Million, with a yearly change of -36.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $45.77 Million | +82.97% |
| 2024 | $25.02 Million | -39.81% |
| 2023 | $41.56 Million | -54.86% |
| 2022 | $92.07 Million | -36.36% |
| 2021 | $144.68 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of LAVA Therapeutics NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.77 Million USD |
| MoneyControl | $45.77 Million USD |
| MarketWatch | $45.77 Million USD |
| marketcap.company | $45.77 Million USD |
| Reuters | $45.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more